News

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need.   These findings suggest that leronlimab’s anti-fibrotic…

READ MORE

On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH.   ► FDA NEWS RELEASE FDA approved first MASH treatment     It took more than 15 years for Rezdiffra to be approved for the treatment of MASH,…

READ MORE

On February 15, World Cholangiocarcinoma Day!   Today we would like to introduce cholangiocarcinoma (CCA, bile duct cancer) and its risk factor, primary sclerosing cholangitis (PSC).   CCA is the second most common liver cancer after hepatocellular carcinoma, and its incidence appears to be increasing worldwide (Banales JM et al., Nat Rev Gastroenterol Hepatol. 2020)….

READ MORE

We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For details, please refer to the following URL.     SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field URL ► https://kyodonewsprwire.jp/release/202402076294    …

READ MORE

Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM (JST).   In this webinar, we will introduce the drug evaluation study with GLP-1. That is why we highly recommend that you join our free webinar!   Webinar Link ►►►　Click here    …

READ MORE

Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on.   Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…

READ MORE

November 15th is World COPD Day, so why not learn more about COPD？   What is World COPD Day? World COPD Day was established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness, share knowledge, and discuss ways to reduce the burden of COPD worldwide. GOLD is a global organization promoting…

READ MORE

Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in liver cirrhosis due to NASH/MASH   For detailed information, see the below URL.   Press Release Galectin Therapeutics Reports the Positive Outcome of the…

READ MORE

The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new drug candidate for non-alcoholic steatohepatitis (NASH).   The BTD is designed to expedite the development and review for new drug candidates and  recognized by the U.S. FDA as promising for the treatment of serious or fatal diseases for which no…

READ MORE